



Hepatitis E virus infection in high-risk populations in Osun State, Nigeria

Folakemi Abiodun Osundare^{a,b}, Patrycja Klink^c, Olusola Aanuoluwapo Akanbi^{a,c}, Bo Wang^{c,d}, Dominik Harms^c, Olusola Ojuronbe^a, Moses Adedapo Ajayi^b, Emmanuel Oluwagbenga Babaranti^e, C.-Thomas Bock^{c,f,*}, Oladele Oluyinka Opaleye^{a,c,1}

^a Department of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Osogbo, Nigeria

^b Science Laboratory Technology Department, Federal Polytechnic Ede, Ede, Nigeria

^c Department Infectious Diseases, Viral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Robert Koch Institute, Berlin, Germany

^d Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA

^e Department of Environmental Management and Toxicology, National Open University of Nigeria, Abuja, Nigeria

^f Institute of Tropical Medicine, University of Tuebingen, Tuebingen, Germany

ARTICLE INFO

Keywords:

Hepatitis E virus
Risk population
HEV antibodies
ELISA
RT-PCR
Nigeria

ABSTRACT

Hepatitis E virus (HEV) infection is an emerging infection that is of major public health concern, especially in some vulnerable groups like immunosuppressed individuals, pregnant women and HBV-coinfected individuals. HEV is transmitted faecal/oral or zoonotically depending on the HEV-genotype. This study aimed at investigating HEV infections among different at-risk populations in Osun State, Southwestern Nigeria. A total of 720 serum samples were collected from animal handlers, pregnant women, people living with HIV/AIDS, and Hepatitis B virus (HBV) infected individuals. Commercially available Enzyme-Linked Immunosorbent Assays (ELISA) were used for the detection of anti-HEV total and IgM antibodies. Polymerase chain reaction (PCR) was carried out in the HEV seropositive samples and all the samples from individuals infected with HBV. Descriptive analysis and chi-square test of association were performed.

The anti-HEV total antibody seroprevalence in HIV-positive individuals, animal handlers and pregnant women was 11.4% ($n = 47/411$), 7.9% ($n = 7/89$), and 6.3% ($n = 10/160$), respectively. Markers of acute HEV infection (anti-HEV IgM) were detected in 2.2% of HIV-positive individuals ($n = 9/411$) and 1.8% of animal handlers ($n = 2/89$), respectively, and in 0.6% of pregnant women ($n = 1/160$). However, all samples were HEV RNA negative.

This study analysed the presence of markers of HEV infection among different at-risk populations without clinical symptoms of HEV infection. Our results showed that HEV is an underestimated threat to public health in Nigeria and underlines the need of an HEV surveillance system to understand the distribution and transmission of HEV infection in animals and/to humans.

1. Introduction

Hepatitis E virus (HEV) has emerged as a threat to public health, with an estimated number of 70,000 deaths from genotypes 1 and 2 globally [1]. HEV is a quasi-enveloped, single-stranded, positive-sense RNA virus with a genome size between 6.4 and 7.2 kb [2,3]. Classified into the *Hepeviridae* family *Orthohepevirus A*, HEV has eight known genotypes of which four are pathogenic to humans (HEV-genotypes 1–4); however, the HEV-genotype 7 initially found in dromedary could be also detected in immunosuppressed individuals [4,5].

HEV-genotypes 1 and 2 (HEV-1 and -2) are transmitted via the faecal-oral route and exclusively infect humans. Infections with HEV-1 can be more severe in pregnant women, where case fatality rates up to 25% have been reported [6]. Also, certain population groups like immunosuppressed persons and individuals with pre-existing liver disease are more vulnerable to infections with HEV [7]. HEV genotypes 3 and 4, on the other hand, have been found in both humans and animals and are transmitted zoonotically via the ingestion of raw or undercooked meat and close contact to infected animals [4]. Furthermore, HEV-3 and -4 can lead to chronic infections, especially in

* Corresponding author at: Robert Koch Institute, D-13353 Berlin, Germany.

E-mail address: Bockc@rki.de (C.-T. Bock).

¹ C.T.B. and O.O.O. contributed equally to this work and thus shared last authorship.

<https://doi.org/10.1016/j.onehlt.2021.100256>

Received 31 August 2020; Received in revised form 26 April 2021; Accepted 26 April 2021

Available online 28 April 2021

2352-7714/© 2021 The Authors.

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

immunocompromised individuals. In patients with chronic HBV infection, super-infection with HEV is a common cause of liver failure, accounting for 20% of cases in regions endemic for HEV [8,9]. Furthermore, in some studies [10] a higher HEV seroprevalence in individuals with HBV-related liver disease in comparison to healthy individuals has been observed.

In Nigeria, only a few HEV seroprevalence studies have been performed until today which detected a seroprevalence (IgG and total antibodies) between 7.0%–66.7% in different populations [11–13]. In one study, the prevalence of HBV/HEV coinfection was analysed in Nigerian healthcare workers, reporting a coinfection rate of 27.3% [14]. Furthermore, an anti-HEV IgM antibody seroprevalence between 0.4%–9.0% was reported [13,15,16]. Two outbreaks of HEV have been documented in Nigeria; one small outbreak in Port Harcourt South-South Nigeria involving ten people between November 1997–June 1998 [17] and a recent outbreak in 2017 with about 1815 individuals including pregnant women and a case fatality rate of 0.6% in Bornu State, Northeast Nigeria [18]. While during the first outbreak, only HEV-2 was reported, the second outbreak was caused both by genotypes 1 and 2 [19,20]. There is a dearth of information on HEV infection in Nigeria, especially in at-risk populations. Therefore, this study aimed to analyse the prevalence of serological markers of HEV infection and/or HEV RNA in HIV-positive individuals, HBV-positive individuals, animal handlers and pregnant women.

2. Materials and methods

2.1. Sampling

A total of 660 serum samples were collected from consenting human participants that included apparently healthy animal handlers ($n = 89$; of which pig farmers $n = 15$ and cow butchers $n = 74$), pregnant women ($n = 160$) and HIV-infected individuals ($n = 411$) in Osun State, Southwestern Nigeria (Table 1). Convenience sampling technique [21] was used in recruiting the study participants, and demographic data were obtained. Samples were collected between February 2014 to May 2017.

2.2. Ethical approval

The Health Planning Research and Statistics Department of Osun State Ministry of Health gave the ethical clearance (OSHREC/PRS/569 T/52) for this study. Informed consent for participants under the age of 18 years was obtained from consenting parents or guardians. The molecular analysis also included 60 serum samples from HBV-infected individuals collected in 2014 from outpatients in three tertiary hospitals from an initial study [22].

2.3. Serology

To detect anti-HEV total antibodies, samples were analysed using the MP diagnostics HEV ELISA 4.0 (MP Biomedicals Asia Pacific, Singapore). Samples positive for anti-HEV total antibodies were further

Table 1
Samples and sources.

Samples (n)	Source
Animal handlers (89)	Cow handlers (74) Pig handlers (15)
Pregnant women (160)	Farms and Association meeting
HIV-infected Individuals (411)	Antenatal clinics around the State Capital (5 clinics)
HBV-infected individuals (60)	HIV Clinic (Institute of Human Virology, Nigeria Clinics LAUTECH Osogbo) Outpatients [24]

screened for acute infection using the MP diagnostics HEV IgM ELISA 3.0 (MP Biomedicals Asia Pacific, Singapore). For the samples of HBV-infected individuals only PCR was performed due to the low sample material.

2.4. RT-PCR and genotyping

RNA was extracted from a 140 μ l mixture (135 μ l serum and 5 μ l MS2 phage-internal control) by using the QIAmp Viral RNA kit (Qiagen, Hilden, Germany) and the QiaCUBE robotic machine according to the manufacturer's instruction. The extracted products were stored at -80°C before use.

HEV RNA detection and subsequent genotyping of samples positive for anti-HEV total antibodies and the samples from HBV-infected individuals was performed using two different PCR assays: a one-step RT-nested PCR and a one-step RT-semi-nested PCR assay with primers lying in the ORF 1 and ORF 2 region of the HEV genome, respectively (Table 2). Primers were designed based on conserved regions in multiple sequence alignments of the ORF 1 and ORF 2 region of HEV-1 - HEV-4 [23]. The primers were made available by the FG 15 group of the Robert Koch Institute Berlin, Germany.

The same amplification conditions were used for the ORF 1 and ORF 2 PCR assays as described previously [13]. Briefly, the first-round PCR was performed in a volume of 25 μ l (5.8 μ l water, 5 μ l $5\times$ RT/PCR buffer (2.5 mM Mg), 5 μ l $5\times$ Q-solution, 1 μ l 10 mM dNTP's, 1 μ l of antisense primer, 1 μ l of sense primer, 0.2 μ l RNasin (400u/ μ l), 1 μ l enzyme mix (RT/TaqPol) and 5 μ l template) using the Qiagen One-Step RT-PCR Kit (Qiagen, Hilden, Germany) and a Biometra Trio thermocycler (Biometra, Jena, Germany). Cycling conditions for the first reaction were 50°C for 30 min, 95°C for 5 min followed by 10 cycles of 95°C for 30 s, 60°C ($-1/\text{cycle}$) for 30 s, 72°C for 45 s, and another 35 cycles at 95°C for 30 s, 52°C for 30 s, 72°C for 45 s and a final extension at 72°C for 7 min.

Twenty-five microlitre volumes containing 10.5 μ l of water, 0.5 μ l of sense and antisense primer, 12.5 μ l Hot start Master Mix (Qiagen, Hilden, Germany) and 1 μ l template- product from the first-round PCR was used for the second-round PCR.

Cycling parameters for the nested and semi-nested PCR were as follows: 95°C for 10 min, followed by 40 cycles at 94°C for 30 s, 52°C for 30 s, 72°C for 45 s), with a final extension at 72°C for 5 min. A plasmid containing the HEV genotype 3 (HEV_RKI [GenBank accession no. FJ956757]) served as positive control.

2.5. Statistical analysis

The data generated from this study were analysed anonymously using descriptive analysis and chi-square for the test of association with STATA package version 14.2 (StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP). Significance was set at $p < 0.05$ and X^2 is the Pearson chi square value. The descriptive analyses are presented as simple percentages and interquartile range.

Table 2
Primer sequences.

	Sequence (5'-3')	^a Location	Polarity
ORF 1			
HEV-38	GAGGCYATGGTSGAGAARG	4084–4102	+
HEV-39	GCCATGTTCCAGACRGRTRTCC	4622–4601	–
HEV-37	GGTCCGYGCTATTGARAARG	4277–4297	+
HEV-27	TCRCCAGAGTGYTTCTTCC	4583–4565	–
ORF 2			
HEV-30	CCGACAGAATTGATTCGTCGG	6296–6317	+
HEV-31	GTCTTGARTACTGCTGR	6750–6733	–
HEV-32	GTCTCAGCCAATGGCGAGCCRAC	6350–6372	+

^a Based on HEV-1 GenBank accession number M73218

3. Results

3.1. Characteristics of the study cohort

In total, 720 serum samples from HIV-positive individuals, animal handlers, HBV-infected individuals and pregnant women were analysed for markers of HEV infection. The total study participants were mainly female (70.7%; $n = 509/720$) and had a median age of 34.5 years (IQR:28–42). The median age in the HIV-infected individuals, animal handlers, pregnant women and HBV-positive individuals was 39 (IQR: 33–47), 35 (IQR: 27–45), 27 (IQR: 24–31.5) and 32 (IQR: 24.5–39) respectively (Table 3). Of the 160 pregnant women, 27.5% ($n = 44/160$) were in the first trimester, while 48.8% ($n = 78/160$) and 23.8% ($n = 38/160$) were in the second and third trimester, respectively. Of the sixty individuals with HBV, 48.3% ($n = 29/60$) were female and 51.7% ($n = 31/60$) were male. The treatment status of the HBV- and HIV-infected individuals is not known.

3.2. Anti-HEV seroprevalence

The seroprevalence of anti-HEV total antibodies was highest in HIV-positive individuals 11.4% ($n = 47/411$), followed by animal handlers 7.9% ($n = 7/89$) and pregnant women 6.3% ($n = 10/160$) (Table 4). For anti-HEV IgM, a seroprevalence of 2.2% was detected in both, HIV-positive individuals and animal handlers ($n = 9/411$ and $n = 2/89$, respectively), while in pregnant women 0.6% of individuals ($n = 1/160$) were anti-HEV IgM-positive. In the HIV-positive individuals, the highest seroprevalence of both anti-HEV total and IgM antibodies was detected in the age group of >60 year olds (22.7%; $n = 5/22$ and 9.1%; $n = 2/22$) (Table 4). In contrast, in the animal handlers only individuals <40 years of age tested positive for anti-HEV total and IgM antibodies. In the subgroup of pregnant women, the highest anti-HEV total antibody seroprevalence was detected in the age group of 10–19 year olds.

In the HIV-positive individuals, the seroprevalence of anti-HEV total and IgM antibodies was higher in men (total antibodies: 13.9%; IgM: 6.5%) than in women (total antibodies: 10.6%; IgM: 0.7%). None of the women from the animal handler's cohort was positive for anti-HEV antibodies (total and IgM), while in men a prevalence of anti-HEV total antibodies and IgM was detected in 9.7% ($n = 7/72$) and 2.8% ($n = 2/72$), respectively. In the animal handlers anti-HEV antibodies were exclusively detected in cow butchers (total antibodies; 9.5%; IgM: 2.7%).

A statistical significance was only found for the anti-HEV IgM seroprevalence in HIV-infected individuals, which was significantly higher in men than in women ($p < 0.01$) (Table 5). In the different stages of pregnancy, the highest seroprevalence of anti-HEV total antibodies was detected in women in the second trimester with 7.7% ($n = 6/78$) followed by first trimester 6.8% ($n = 3/44$), and least in the third trimester, 2.6% ($n = 1/38$) (Table 6). Anti-HEV IgM antibodies were detected in only one woman (1.3%) in the second trimester.

Table 3
Age and gender distribution.

		HIV-positive individuals n (%)	Animal handlers n (%)	Pregnant women n (%)	HBV-positive individuals n (%)
Total		411	89	160	60
Gender	Male	108 (26.0)	72 (80.9)	–	29 (48.3)
	Female	303 (73.7)	17 (19.1)	160 (100)	31 (51.7)
Age (years)	0–9	7 (1.7)	–	–	1 (1.7)
	10–19	6 (1.5)	4 (4.5)	13 (8.3)	6 (10)
	20–29	44 (10.7)	20 (22.5)	94 (58.8)	15 (25)
	30–39	156 (38.0)	29 (32.6)	53 (33.1)	25 (41.7)
	40–49	123 (30.0)	17 (19.1)	–	6 (10)
	50–59	53 (13.0)	10 (11.2)	–	5 (8.3)
	>60	22 (5.4)	9 (10.1)	–	2 (3.3)
Median age		39	35	27	32
IQR		33–47	27–45	24–31.5	24.5–39

N = number; IQR = interquartile range.

3.3. PCR detection of HEV

All samples, which tested positive for anti-HEV total antibodies ($n = 64$) and individuals infected with HBV ($n = 60$) were subjected to PCR analyses for the detection of HEV RNA. However, all samples were tested negative for HEV RNA.

4. Discussion

In this study, the anti-HEV seroprevalence was analysed in populations at risk for HEV infection, namely HIV-positive individuals, animal handlers and pregnant women. The highest seroprevalence (total antibodies) was detected in HIV-positive individuals (11.4%), followed by animal handlers (7.9%) and pregnant women (6.3%). None of the samples was tested positive for HEV RNA.

In this study, 11.4% of HIV-infected individuals tested positive for anti-HEV total antibodies indicating that this group is at higher risk of acquiring HEV infection compared to the other groups analysed here. Moreso, acute HEV infection is correlated with a higher mortality rate in individuals with underlying liver disease, which is often present in HIV-infected individuals due to coinfection with hepatitis B or C virus [24]. This calls for close monitoring of people living with HIV for better care and management. While the seroprevalence observed in this study is lower than seroprevalences reported from HIV-positive individuals from other African countries where HEV is endemic [25,26], it is in line with the results reported from studies in Nigeria, where anti-HEV seroprevalences of 5.5% in Ogbomoso (South-West) [27], 11.1% in Oyo state (South-West) [28] and 31.1% in Plateau state (North-Central) [12] were detected. The total anti-HEV IgM seroprevalence detected in this study (1.8%, $n = 12/660$) is similar to studies observed in different regions of Nigeria. The anti-HEV IgM seroprevalence observed among people living with HIV in this study (2.2%) is comparable with the seroprevalences observed among HIV-positive individuals in Ibadan and Plateau State, Nigeria, where a seroprevalence of 1.7% and 1.3%, was reported, respectively [12,28].

Although there was no statistically significant difference in the seroprevalence of anti-HEV total antibodies in male and female HIV-positive study participants (13.9% in men vs 10.6% in women), the seroprevalence of anti-HEV IgM was significantly higher in men (6.5%) than in women (0.7%). Also, all the HEV total antibodies and HEV IgM was only found in male among animal handlers. A possible factor might be the intake of alcohol, as in Nigeria, men are more involved in alcoholism [29] which has been described as a cofounding risk factor for HEV infection [13]. Alcohol may destroy the liver integrity increasing the susceptibility to viral infections [7,30]. It could also mean that females engage in better personal hygiene practices than males [31].

The seroprevalence of anti-HEV total antibodies in animal handlers in this study (7.9%) is lower than the seroprevalence reported from animal handlers (66.3%) in Plateau State, Nigeria [12]. Also, anti-HEV IgM seroprevalence reported from animal handlers in this study

Table 4
Age distribution and subgroup seroprevalence of anti-HEV antibodies.

		Seroprevalence n (%)					
		HIV-positive individuals (n = 411)		Animal handlers (n = 89)		Pregnant women (n = 160)	
		Anti-HEV total antibodies	Anti-HEV IgM	Anti-HEV total antibodies	Anti-HEV IgM	Anti-HEV total antibodies	Anti-HEV IgM
Total		47 (11.4)	9 (2.2)	7 (7.9)	2 (2.2)	10 (6.3)	1 (0.6)
Age (years)	0–9	0	0				
	10–19	1 (0.2)	0	0	0	1 (7.7)	0
	20–29	4 (9.1)	1 (2.3)	3 (15.0)	0	5 (5.3)	0
	30–39	18 (11.5)	3 (1.9)	2 (6.9)	1 (3.45)	4 (7.6)	1 (1.9)
	40–49	12 (9.8)	1 (0.8)	2 (11.8)	1 (5.88)		
	50–59	7 (13.2)	2 (3.5)	0	0		
	≥60	5 (22.7)	2 (9.1)	0	0		
p-Value (X ²)		0.598 (4.583)	0.326 (6.945)	0.584 (3.763)	0.821 (2.202)	0.845 (0.337)	0.362 (2.032)

Table 5
Distribution of anti-HEV antibodies according to HIV status, gender, and animal type.

Subgroup		Anti-HEV total antibodies	Anti-HEV IgM
		Positive n (%)	Positive n (%)
HIV-positive individuals-by gender	Male (n = 108)	15 (13.9)	7 (6.5)
	Female (n = 303)	32 (10.6)	2 (0.7)
p value (X ²)		0.351 (0.871)	0.000 (12.598)
Animal handlers-by gender	Male (n = 72)	7 (9.7)	2 (2.8)
	Female (n = 17)	0	0
p value (X ²)		0.180 (1.794)	0.487 (0.483)
Animal handlers-by type of animal	Cow handlers (n = 74)	7 (9.5)	2 (2.7)
	Pig handlers (n = 15)	0 (0)	0 (0)
p value (X ²)		0.215 (1.540)	0.520 (0.415)

Table 6
Distribution of anti-HEV antibodies according to pregnancy stage.

	Seroprevalence n (%)	
	Anti-HEV total antibodies	Anti-HEV IgM
First trimester (n = 44)	3 (6.8)	0
Second trimester (n = 78)	6 (7.7)	1 (1.3)
Third trimester (n = 38)	1 (2.6)	0
p value (X ²)	0.563 (1.150)	0.589 (1.058)

(2.2%) is lower than the seroprevalence reported among animal handlers in Plateau State (8.33%). According to studies by Hoan et al., [32] and Junaid et al., [12] animal handlers and especially pig handlers were at risk of HEV which may explain the discrepancy with the results found here. In this study, most of the animal handlers dealt with cows while only a few handled pigs. However, it is worthy of note that none of the pig farmers was positive for anti-HEV antibodies in this study. This may be due to the small sample size of the pig handlers (n = 15). Furthermore, a higher seroprevalence of HEV has been found in pigs in the North-central and North-eastern Nigeria as compared with the South-western and South-southern regions [33]. As such, an increased seroprevalence in the animal handlers from Plateau State, North-central Nigeria may be due to zoonotic transfer from direct contact with infected animals, and infected animal faecal samples, among other routes of HEV transmission.

To the best of our knowledge, cows in Nigeria have not been found positive for HEV infection, but antibodies have been found in goats, sheep and pigs [34]. This might be a pointer that the route of

transmission of HEV in animal handlers in this study could be from other routes like contaminated water, not zoonotic transfer. Nevertheless, markers of HEV infection have been detected in cows [35] and HEV has also been isolated from cow milk [36,37], so that a zoonotic transmission cannot be excluded.

All the HEV-seropositive samples were observed in male animal handlers. Animal handling is more of a male job than a female role in the Nigeria setting, and the number of female animal handlers was rather low.

In this study, an anti-HEV total antibody seroprevalence of 6.3% in pregnant women has been observed which in comparison is lower than the seroprevalence reported from pregnant women in Plateau State, Nigeria (42.6%) [12] and Ghana (12.31%) [38] but closer to the anti-HEV IgG seroprevalence (5.7%) recorded in Mexico [39]. Most of the pregnant women recruited in the study of Junaid et al., [12] were from the rural community of Plateau State while most of the women in this study were from the urban region. The anti-HEV IgM seroprevalence observed among pregnant women in this study (0.6%) is comparably similar to the results from the studies of Obiri-Yeboah et al., [38] in Ghana and Ifeorah et al., [15] in pregnant women in Ibadan, Nigeria (anti-HEV IgM seroprevalence: 0.2% and 0.4% respectively).

The only anti-HEV IgM positive pregnant woman was in the age range of 30–39 years and in the second trimester of pregnancy. HEV infection in the third trimester of pregnancy has been associated with a high fetomaternal mortality rate [40]. HEV has been found to take a more aggressive course in pregnant women in comparison to non-pregnant women than any other hepatotropic virus as reported by several authors [40,41]. The high maternal-child mortality rate in Nigeria [42] may be partly due to HEV infection as Krain et al. [43] suggested that HEV might be the underlying cause of more than 3000 stillbirths occurring annually in developing countries. These claims are substantiated with the HEV outbreak that occurred in Bornu State, Northeast of Nigeria, where a case fatality of 0.6% was recorded; infected pregnant women inclusive [44]. It is therefore expedient to enlighten this group of people on the need for better hygiene and the employment of HEV vaccine to prevent HEV infection in women of reproductive age.

A limitation of our study may be that the sample size is somewhat small; however, in our opinion 660 samples divided in three subgroups will generate valid comparison and statistics. The disparities in the seroprevalences observed in this study compared to other studies may be attributed to the prevailing conditions that operate in rural areas of a low-income country such as inadequate potable water, poor living conditions, poor nutritional status, and ill-equipped health facilities [45] which are known to be associated with a higher risk of HEV infection. Various factors fuelling the transmission of HEV in different localities, sample size and differences in sensitivities of the assays used may account for the differences in anti-HEV seroprevalences in individuals within Nigeria and across Africa. Furthermore, foodborne transmission could be a factor for the different anti-HEV seroprevalences

observed in different regions of Nigeria. Junaid et al. observed a significant association between improper washing of fruit and vegetables and anti-HEV IgG seroprevalence [12]. In comparison to Osun State, in Plateau State, ready to eat vegetables such as apples, pear, cabbages, and lettuce, among others are grown and more widely consumed [46]. Some of these vegetables and fruits may have been contaminated as farmers may have used both untreated animal and human faecal samples as manure in place of inorganic fertilisers that must be purchased. The assertion of faecal contamination of vegetables is supported by the findings of Pam et al., [47] in vegetables sold in different markets in south Jos. Vegetables and fruits have been implicated as a vehicle for transmission of HEV in some countries [48,49].

All the HBV infected serum sample were negative for HEV RNA. Due to the suboptimal quantity of the serum, the serological evidence of HEV could not be carried out. However, coinfection of HBV with other viral infections such as HIV, HDV and HCV has been documented to shape the clinical course of HBV infection [22,50]. Chronic hepatitis B-related cirrhosis and intermediate to high HBV DNA level have been associated with severe disease in superinfected patients with HEV [10,51]. Until so far only one study analysed the prevalence of HEV/HBV coinfection in Nigeria, reporting 37.5% of healthcare workers being positive for HEV and HBV coinfection [14]. Large-scale surveillance should be carried out to understand the biology of HEV in HBV infected individuals fully.

None of the samples tested was positive for HEV RNA. However, false-negative result cannot be ruled out in individuals with lower HEV viral load than the detection limit of the ORF 1 nested and 2 semi-nested PCRs (1×10^4 copies/ml and 1×10^3 copies/ml, respectively) used for the analyses.

5. Conclusion

While HEV infection is still a neglected disease in Nigeria, the data from this study shows that HEV is of major health concern with a significant number of individuals being exposed to HEV. Therefore, the awareness of this disease should be increased by systematic screening, especially of at-risk populations having contact to zoonotically transmitted HEV.

Author contributions

Conceptualization: Folakemi A. Osundare, C.-Thomas Bock, Oladele O. Opaleye. **Data curation:** Folakemi A. Osundare. **Formal analysis:** Folakemi A. Osundare, Patrycja Klink. **Investigation:** Folakemi A. Osundare, Emmanuel O. Babaranti, Bo Wang, Olusola A. Akanbi. **Methodology:** Folakemi A. Osundare, C.-Thomas Bock, Oladele O. Opaleye. **Project administration:** C.-Thomas Bock, Oladele O. Opaleye. **Resources:** Folakemi A. Osundare, C.-Thomas Bock, Oladele O. Opaleye. **Software:** Folakemi A. Osundare, Bo Wang, Dominik Harms, Patrycja Klink. **Supervision:** C.-Thomas Bock, Olusola Ojurongbe, Oladele O. Opaleye. **Validation:** Folakemi A. Osundare, Moses A. Ajayi, Oladele O. Opaleye. **Visualization:** Folakemi A. Osundare, Dominik Harms, Patrycja Klink. **Writing—original draft preparation:** Folakemi A. Osundare. **Writing—review and editing:** Folakemi A. Osundare, Olusola Ojurongbe, Patrycja Klink, C.-Thomas Bock.

Funding resources

This study was supported by a grant from the German Federal Ministry of Health regarding a decision of the German Bundestag by the Federal Government (NiCaDe-Project grant No: ZMVI-2519GHP711, and CHED-Project grant No: ZMVI-2518FSB705). F.A.O. and O.O.O. are funded by a sub-project of the Global Health Protection Programme supported by the German Federal Ministry of Health based on a decision by the German Bundestag, the Partnership in Postgraduate Education (PPE), Robert Koch Institute, Berlin, Germany. O.A.A. is supported by funding of DAAD, Germany (German Academic Exchange Service; grant

ID 57299293). B.W. is supported by the China Scholarship Council (CSC), Beijing, China. D.H. is supported by the Claussen-Simon-Stiftung (Claussen-Simon Foundation; CSF) “Dissertation Plus” program, Germany, and the Fazit-Stiftung, Germany, “Promotions Stipendium”. The funders BMG, CSC, DAAD, Fazit, CSF, and GHPP/PPE had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The content is the responsibility only of the authors and does not represent the views of the funders.

Declaration of Competing Interest

The authors declare that they have no known competing financial interest and personal relationship that could inappropriately influence the presented work.

Acknowledgments

We are grateful to Olamide Omopo (LAUTECH), Adeolu Oluremi (LAUTECH), Marcel Schulze (RKI), Steffen Zander (RKI), and Hannes Jarmuth (RKI) for their excellent technical assistance.

References

- [1] D.B. Rein, G.A. Stevens, J. Theaker, J.S. Wittenborn, S.T. Wiersma, The global burden of hepatitis E virus genotypes 1 and 2 in 2005, *Hepatology* 55 (2012) 988–997, <https://doi.org/10.1002/hep.25505>.
- [2] M.A. Purdy, T.J. Harrison, S. Jameel, X.-J. Meng, H. Okamoto, W.H.M. Van der Poel, D.B. Smith, ICTV virus taxonomy profile: hepeviridae, *J. Gen. Virol.* 98 (2017) 2645–2646, <https://doi.org/10.1099/jgv.0.000940>.
- [3] Y. Nan, Y.J. Zhang, Molecular biology and infection of hepatitis E virus, *Front. Microbiol.* 7 (2016) 1–21, <https://doi.org/10.3389/fmicb.2016.01419>.
- [4] G.W. Webb, H.R. Dalton, Hepatitis E: an underestimated emerging threat, *Ther. Adv. Infect. Dis.* 6 (2019), <https://doi.org/10.1177/2049936119837162>, 204993611983716.
- [5] D.B. Smith, P. Simmonds, S. Jameel, S.U. Emerson, T.J. Harrison, X.J. Meng, H. Okamoto, W.H.M. Van der Poel, M.A. Purdy, Consensus proposals for classification of the family Hepeviridae, *J. Gen. Virol.* 95 (2014) 2223–2232, <https://doi.org/10.1099/vir.0.068429.0>.
- [6] Strategic Advisory Group of Experts on Immunization, Hepatitis E: Epidemiology and Disease Burden. https://www.who.int/immunization/sage/meetings/2014/october/1_HEV_burden_paper_final_03_Oct_14_yellow_book.pdf?ua=1, 2015 (accessed August 28, 2020).
- [7] H.R. Dalton, R.P. Bendall, M. Rashid, V. Ellis, R. Ali, R. Ramnarace, W. Stableforth, W. Headdon, R. Abbott, C. McLaughlin, E. Froment, K.J. Hall, N.P. Michell, P. Thatcher, W.E. Henley, Host risk factors and autochthonous hepatitis E infection, *Eur. J. Gastroenterol. Hepatol.* 23 (2011) 1200–1205, <https://doi.org/10.1097/MEG.0b013e32834ca4da>.
- [8] M. Kumar, B.C. Sharma, S.K. Sarin, Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease, *J. Gastroenterol. Hepatol.* 23 (2008) 883–887, <https://doi.org/10.1111/j.1440-1746.2007.05243.x>.
- [9] G. Scotto, F. Aucella, G. Grandaliano, D. Martinelli, M. Querques, A. Gesuete, B. Infante, P.D. Carri, S. Massa, G. Salatino, F. Bulla, V. Fazio, Hepatitis E in hemodialysis and kidney transplant patients in south-east Italy, *World J. Gastroenterol.* 21 (2015) 3266–3273, <https://doi.org/10.3748/wjg.v21.i11.3266>.
- [10] N.X. Hoan, H. Van Tong, N. Hecht, B.T. Sy, P. Marcinek, C.G. Meyer, L.H. Song, N. L. Toan, J. Kurreck, P.G. Kreamsner, C.T. Bock, T.P. Velavan, Hepatitis E virus superinfection and clinical progression in hepatitis B patients, *EBioMedicine* 2 (2015) 2080–2086, <https://doi.org/10.1016/j.ebiom.2015.11.020>.
- [11] E. Ekanem, J. Ikobah, H. Okpara, J. Udo, Seroprevalence and predictors of hepatitis e infection in nigerian children, *J. Infect. Dev. Ctries.* 9 (2015) 1220–1225, <https://doi.org/10.3855/jidc.6736>.
- [12] S.A. Junaid, S.E. Agina, K.A. Abubakar, Epidemiology and associated risk factors of hepatitis E virus infection in Plateau State, Nigeria, *Virol. Res. Treat.* 5 (2014) 15–26, <https://doi.org/10.4137/VRT.S15422>.
- [13] F.A. Osundare, P. Klink, C. Majer, O.A. Akanbi, B. Wang, M. Faber, D. Harms, C.-T. Bock, O.O. Opaleye, Hepatitis E virus seroprevalence and associated risk factors in apparently healthy individuals from Osun State, Nigeria, *Pathogens* 9 (2020) 392, <https://doi.org/10.3390/pathogens9050392>.
- [14] S.O.O. Ola, G.N.N. Odaibo, O.D.D. Olaleye, E.A. Ayoola, Hepatitis B and E viral infections among Nigerian healthcare workers, *Afr. J. Med. Med. Sci.* 41 (2012) 387–391. <http://www.ncbi.nlm.nih.gov/pubmed/23672103>.
- [15] I.M. Ifeorah, T.O.C. Faleye, A.S. Bakarey, M.O. Adewumi, A. Akere, E.C. Omoruyi, A.O. Ogunwale, J.A. Adeniji, Acute hepatitis E virus infection in two geographical regions of Nigeria, *J. Pathog.* 2017 (2017) 1–6, <https://doi.org/10.1155/2017/4067108>.
- [16] A. Fowotade, O. Akande, A.T. Gbaja, V.O. Ogunleye, A. Ajayi, A.O. Kehinde, Seroprevalence of hepatitis E among restaurant food handlers in Ibadan, Nigeria, *Tanzan. J. Health Res.* 20 (2018), <https://doi.org/10.4314/thrb.v20i3.2>.

- [17] Y. Buisson, M. Grandadam, E. Nicand, P. Cheval, H. van Cuyck-Gandre, B. Innis, P. Rehel, P. Coursaget, R. Teyssou, S. Tsarev, Identification of a novel hepatitis E virus in Nigeria, *J. Gen. Virol.* 81 (2000) 903–909, <https://doi.org/10.1099/0022-1317-81-4-903>.
- [18] Nigeria-Centre-for-Disease-Control, *Weekly Situation Report of HEV Outbreak in Borno State No. 15: Epi Weeks 05–06 2018, Borno State, 2018*.
- [19] O.A. Akanbi, D. Harms, B. Wang, O.O. Opaleye, O. Adesina, F.A. Osundare, A. Ogunniyi, D. Naidoo, I. Devaux, A. Wondimagegnehu, C. Peter, O. Ifeanyi, O. Ogundiran, U. Ugochukwu, N. Mba, S.A. Omilabu, C. Ihekweazu, C.-T. Bock, Complete genome sequence of a Hepatitis E virus genotype 1e strain from an outbreak in Nigeria, 2017, *Microbiol. Resour. Announc.* 8 (2019), <https://doi.org/10.1128/MRA.01378-18>.
- [20] B. Wang, O.A. Akanbi, D. Harms, O. Adesina, F.A. Osundare, D. Naidoo, I. Deveaux, O. Ogundiran, U. Ugochukwu, N. Mba, C. Ihekweazu, C.-T. Bock, A new hepatitis E virus genotype 2 strain identified from an outbreak in Nigeria, 2017, *Virol. J.* 15 (2018) 163, <https://doi.org/10.1186/s12985-018-1082-8>.
- [21] M. Elfi, A. Negida, Sampling methods in clinical research; an educational review, *Emerg (Tehran, Iran)* 5 (2017) e52. <http://www.ncbi.nlm.nih.gov/pubmed/28286859>.
- [22] O.O. Opaleye, O.M. Japhet, O.M. Adewumi, E.C. Omoruyi, O.A. Akanbi, A. S. Oluremi, B. Wang, H. van Tong, T.P. Velavan, C.-T. Bock, Molecular epidemiology of hepatitis D virus circulating in Southwestern Nigeria, *Virol. J.* 13 (2016) 61, <https://doi.org/10.1186/s12985-016-0514-6>.
- [23] B. Wang, D. Harms, C.P. Papp, S. Niendorf, S. Jacobsen, M. Lütgehetmann, S. Pischke, H. Wedermeyer, J. Hofmann, C.-T. Bock, Comprehensive molecular approach for characterization of Hepatitis E Virus genotype 3 variants, *J. Clin. Microbiol.* 56 (2018), <https://doi.org/10.1128/JCM.01686-17>.
- [24] A. Rivero-Juarez, F. Cuenca-Lopez, A. Martinez-Peinado, A. Camacho, L.M. Real, M. Frias, A. Gordon, S. Cantisán, J. Torre-Cisneros, J.A. Pineda, A. Rivero, Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: a prospective longitudinal study, *Zoonoses Public Health* 64 (2017) e60–e64, <https://doi.org/10.1111/zph.12347>.
- [25] T. Feldt, F.S. Sarfo, A. Zoufaly, R.O. Phillips, G. Burchard, J. van Lunzen, J. Jochum, D. Chadwick, C. Awason, L. Claussen, C. Drosten, J.F. Drexler, A. M. Eis-Hübinger, Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon, *J. Clin. Virol.* 58 (2013) 18–23, <https://doi.org/10.1016/j.jcv.2013.05.004>.
- [26] C. Jacobs, C. Chiluba, C. Phiri, M.M. Lisulo, M. Chomba, P.C. Hill, S. Ijaz, P. Kelly, Seroepidemiology of hepatitis E virus infection in an urban population in Zambia: strong association with HIV and environmental enteropathy, *J. Infect. Dis.* 209 (2014) 652–657, <https://doi.org/10.1093/infdis/jit409>.
- [27] O.E. Kolawole, Detection of Hepatitis E virus among HIV infected individuals in Ogbomoso, South-western Nigeria, *Br. J. Virol.* 2 (2015) 62–67, <https://doi.org/10.17582/journal.bjv/2015.2.4.62.67>.
- [28] G.N. Odaibo, D.O. Olaleye, Hepatitis E virus infection in HIV positive ART naive and experienced individuals in Nigeria, *World J. AIDS* 03 (2013) 216–220, <https://doi.org/10.4236/wja.2013.33029>.
- [29] V.O. Lasebikan, B.A. Ola, Prevalence and correlates of alcohol use among a sample of Nigerian semirural community dwellers in Nigeria, *J. Addict.* 2016 (2016) 1–6, <https://doi.org/10.1155/2016/2831594>.
- [30] A.C. Fantilli, J. Trinks, S. Marciano, F. Zárate, D.C. Balderramo, M.G.M. Wassaf, L. Haddad, A. Gadano, J.D. Debes, M.B. Pisano, V.E. Ré, Unexpected high seroprevalence of hepatitis E virus in patients with alcohol-related cirrhosis, *PLoS One* 14 (2019), e0224404, <https://doi.org/10.1371/journal.pone.0224404>.
- [31] A.B. Balogun, *Knowledge, Perception, Practice of Personal Hygiene Among Secondary School Students in Ibadan North West Local Government Area, Ibadan, Oyo State, Nigeria, University of Ibadan, 2015*.
- [32] N.X. Hoan, P.X. Huy, B.T. Sy, C.G. Meyer, T. Van Son, M.T. Binh, D.P. Giang, D. Tu Anh, C.-T. Bock, B. Wang, H. Van Tong, P.G. Kremsner, L.H. Song, N.L. Toan, T. P. Velavan, High Hepatitis E virus (HEV) positivity among domestic pigs and risk of HEV infection of individuals occupationally exposed to pigs and pork meat in Hanoi, Vietnam, *Open Forum Infect. Dis.* 6 (2019), <https://doi.org/10.1093/ofid/ofz306>.
- [33] O.A. Owolodun, P.F. Gerber, L.G. Giménez-Lirola, J.K.P.P. Kwaga, T. Opriessnig, P. F. Gerber, J.K.P.P. Kwaga, First report of hepatitis E virus circulation in domestic pigs in Nigeria, *Am. J. Trop. Med. Hyg.* 91 (2014) 699–704, <https://doi.org/10.4269/ajtmh.14-0144>.
- [34] S.A. Junaid, S.E. Agina, K. Jaiye, Seroprevalence of hepatitis E virus among domestic animals in Plateau State–Nigeria, *Br. Microbiol. Res. J.* 4 (2014) 924–934.
- [35] B. Yan, L. Zhang, L. Gong, J. Lv, Y. Feng, J. Liu, L. Song, Q. Xu, M. Jiang, A. Xu, Hepatitis E virus in yellow cattle, Shandong, Eastern China, *Emerg. Infect. Dis.* 22 (2016) 2211–2212, <https://doi.org/10.3201/eid2212.160641>.
- [36] F. Huang, Y. Li, W. Yu, S. Jing, J. Wang, F. Long, Z. He, C. Yang, Y. Bi, W. Cao, C. Liu, X. Hua, Q. Pan, Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis, *Hepatology* 64 (2016) 350–359, <https://doi.org/10.1002/hep.28668>.
- [37] I.M. Sayed, A.A. Elkhawaga, M.A. El-Mokhtar, Circulation of hepatitis E virus (HEV) and/or HEV-like agent in non-mixed dairy farms could represent a potential source of infection for Egyptian people, *Int. J. Food Microbiol.* 317 (2020) 108479, <https://doi.org/10.1016/j.ijfoodmicro.2019.108479>.
- [38] D. Obiri-Yeboah, Y.A. Awuku, J. Adu, F. Pappoe, E. Obboh, P. Nsiah, D. Amoako-Sakyi, J. Simporé, Sero-prevalence and risk factors for hepatitis E virus infection among pregnant women in the Cape Coast Metropolis, Ghana, *PLoS One* 13 (2018) 1–13, <https://doi.org/10.1371/journal.pone.0191685>.
- [39] C. Alvarado-Esquivel, L.F. Sánchez-Anguiano, J. Hernández-Tinoco, Hepatitis E virus exposure in pregnant women in rural Durango, Mexico, *Ann. Hepatol.* 13 (2014) 510–517, [https://doi.org/10.1016/s1665-2681\(19\)31250-5](https://doi.org/10.1016/s1665-2681(19)31250-5).
- [40] M.T. Pérez-Gracia, B. Suay-García, M.L. Mateos-Lindemann, Hepatitis E and pregnancy: current state, *Rev. Med. Virol.* 27 (2017) 1–8, <https://doi.org/10.1002/rmv.1929>.
- [41] P.D. Bose, B.C. Das, R.K. Hazam, A. Kumar, S. Medhi, P. Kar, Evidence of extrahepatic replication of hepatitis E virus in human placenta, *J. Gen. Virol.* 95 (2014) 1266–1271, <https://doi.org/10.1099/vir.0.063602-0>.
- [42] Y. Li, J. Yang, S. Li, L. Yao, National, regional, and worldwide estimates of stillbirth rates, *Lancet* 378 (2011) 873, [https://doi.org/10.1016/S0140-6736\(11\)61406-2](https://doi.org/10.1016/S0140-6736(11)61406-2).
- [43] L.J. Krain, J.E. Atwell, K.E. Nelson, A.B. Labrique, Review article: fetal and neonatal health consequences of vertically transmitted hepatitis E virus infection, *Am. J. Trop. Med. Hyg.* 90 (2014) 365–370, <https://doi.org/10.4269/ajtmh.13-0265>.
- [44] Borno State Government, Nigeria Health Sector, Northeast Nigeria Response Health Sector Bulletin #36 (November 2017). <http://origin.who.int/health-cluster/countries/nigeria/Borno-Health-Sector-Bulletin-Issue36.pdf>, 2017.
- [45] K.E. Johnson, U. Ifeoma, Rural development as a panacea for rural-urban migration in Nigeria, *Arts Humanit. Open Access J.* 2 (2018) 241–244, <https://doi.org/10.15406/ahoaj.2018.02.00065>.
- [46] M.E. Banwat, L.A. Lar, J. Daboer, S. Audu, S. Lassa, Knowledge and intake of fruit and vegetables consumption among adults in an urban community in North Central Nigeria, *Niger. Heal. J.* 12 (2012). <https://www.ajol.info/index.php/nhj/article/view/81244>.
- [47] D.D. Pam, V.A. Pam, C.C. Bot, M.H. Abdullateef, K.I. Ogbu, Intensity of contamination of vegetables in different markets in Jos South Local Government Area of Plateau State, *Greener, J. Agric. Sci.* 5 (2015) 217–222, <https://doi.org/10.15580/GJAS.2015.6.080315110>.
- [48] J. Brassard, M.-J. Gagné, M. Généreux, C. Côté, Detection of human food-borne and zoonotic viruses on irrigated, field-grown strawberries, *Appl. Environ. Microbiol.* 78 (2012) 3763–3766, <https://doi.org/10.1128/AEM.00251-12>.
- [49] P. Kokkinos, I. Kozyra, S. Lazic, M. Bouwknecht, S. Rutjes, K. Willems, R. Moloney, A.M. de Roda Husman, A. Kaupke, E. Legaki, M. D'Agostino, N. Cook, A. Rzeżutka, T. Petrovic, A. Vantarakis, Harmonised investigation of the occurrence of human enteric viruses in the leafy green vegetable supply chain in three European countries, *Food Environ. Virol.* 4 (2012) 179–191, <https://doi.org/10.1007/s12560-012-9087-8>.
- [50] M.I. Qadir, Hepatitis in AIDS patients, *Rev. Med. Virol.* 28 (2018), e1956, <https://doi.org/10.1002/rmv.1956>.
- [51] C. Chen, S.Y. Zhang, D.D. Zhang, X.Y. Li, Y.L. Zhang, W.X. Li, J.J. Yan, M. Wang, J. N. Xun, C. Lu, Y. Ling, Y.X. Huang, L. Chen, Clinical features of acute hepatitis e super-infections on chronic hepatitis B, *World J. Gastroenterol.* 22 (2016) 10388–10397, <https://doi.org/10.3748/wjg.v22.i47.10388>.